<DOC>
	<DOCNO>NCT03070171</DOCNO>
	<brief_summary>The primary objective trial establish bioequivalence tablet formulation dabigatran etexilate compare commercial capsule formulation follow oral administration fast condition . The secondary objective evaluation comparison several pharmacokinetic parameter treatment .</brief_summary>
	<brief_title>Pradaxa Tablet BE Study Japan</brief_title>
	<detailed_description />
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Subjects include trial , meet follow criterion : Healthy male subject accord investigator 's assessment , base complete medical history include physical examination , vital sign ( blood pressure [ BP ] , pulse rate [ PR ] ) , 12lead electrocardiogram ( ECG ) , clinical laboratory test Age ≥20 ≤40 year old informed consent BMI ≥18 ≤25 kg/m2 screen Signed dated write informed consent prior admission trial accordance Good Clinical Practice ( GCP ) local legislation Subjects allow participate follow general criterion apply : Any find medical examination ( include BP , PR ECG ) deviate normal judge clinically relevant investigator Measurement systolic blood pressure outside range 90 140 mmHg , diastolic blood pressure outside range 50 90 mmHg , pulse rate outside range 45 90 bpm screening . Based clinical judge investigator , repeat measurement allow . Any laboratory value outside reference range randomisation investigator considers clinical relevance Any evidence concomitant disease consider clinically relevant investigator Any relevant bleeding history consider investigator Any history evidence blood dyscrasia , haemorrhagic diathesis , severe thrombocytopenia , cerebrovascular haemorrhage , bleed tendency associate active ulceration overt bleed gastrointestinal , respiratory genitourinary tract disease condition haemorrhagic tendency Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Cholecystectomy and/or surgery gastrointestinal tract could interfere pharmacokinetics trial medication ( except appendectomy simple hernia repair ) Planned surgery within four week follow endof trial examination Diseases central nervous system ( include limit kind seizure stroke ) , relevant neurological psychiatric disorder History relevant orthostatic hypotension , faint spell , blackout Chronic relevant acute infection History relevant allergy hypersensitivity ( include allergy trial medication excipients ) Use drug within 30 day prior administration trial medication might reasonably influence result trial ( incl.Qc/QTc interval prolongation ) Participation another trial investigational drug administer within 60 day prior plan administration trial medication , current participation another trial involve administration investigational drug Smoker ( 10 cigarette 3 cigar 3 pipe per day ) Inability refrain smoke inhouse confinement trial site Alcohol abuse ( consumption 30 g per day : e.g. , 750 mL beer , 1.5 gous [ equivalent 270 mL ] Sake ) Drug abuse positive drug screen Blood donation 100 mL within 30 day prior administration trial medication intend donation trial Intention perform excessive physical activity within one week prior administration trial medication trial Inability comply dietary regimen trial site Subject assess unsuitable inclusion investigator , instance , consider able understand comply trial requirement , condition would allow safe participation trial</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>